|
Welcome to iiCON's quarterly newsletter
|
|
|
Professor Janet Hemingway, iiCON's founding Director
|
|
|
Welcome to the first edition of the Infection Innovation Consortium (iiCON) newsletter.
iiCON is a world-leading collaborative infectious disease R&D programme established in 2020. It brings together industry, academia, and the NHS in a concerted effort with a clear aim: to combat the growing global threat posed by infectious diseases and save lives through collaborative innovation.
Led by Liverpool School of Tropical Medicine, our consortium partners Unilever, Liverpool University Hospitals Foundation Trust, University of Liverpool, Evotec, and Infex Therapeutics are working on number of innovative and ambitious programmes across iiCON’s ten specialist research platforms.
Our quarterly newsletter will provide a unique insight into the work being delivered through the consortium, and the impact this is having in bringing innovative products and therapeutics to patients and communities more quickly, safely, and affordably.
This edition explores iiCON’s Human Challenge platform and the consortium’s work to revolutionise our approach to clinical trials by streamlining and expediting the clinical trial process to support industry innovation.
Human Challenge trials have already played a critical role in our battle to tackle COVID-19 and it will be a key weapon in the arms race to combat the pandemics of the future. Alongside services to industry, academic and NHS partners, we can also provide specialist support in clinicals trial design, ethical approvals and statistical analysis of trial data, for trials in the UK and overseas.
We hope you enjoy this brief update on our work. We look forward to continuing to collaborate with our colleagues and wider community as we come together to pool resources and knowledge in response to the global challenge of infectious disease.
Best wishes,
Professor Janet Hemingway
iiCON founding Director
|
|
Revolutionising the Clinical Trial pathway
The Infection Innovation Consortium (iiCON) is revolutionising the clinical trial landscape through the development of an all-inclusive platform that can support industry at every stage of the clinical trial journey.
|
|
|
iiCON partner Infex progresses novel therapies to clinical trials
Infex Therapeutics is expecting to progress two novel therapeutics to tackle dangerous multi-drug resistant infections into clinical trials over the next 12 months as part of a programme supported by iiCON.
|
|
|
Human Challenge: Small Scale, Big Impact
iCON is changing the unwieldy clinical trials model by offering a ‘fast-track’ Human Challenge smallscale clinical testing model for a growing portfolio of diseases.
|
|
|
Watch our latest video which captures the impact of the Human Challenge programme
|
|
|
|
|
|
